The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant ...

Keros' cash and cash equivalents as of March 31, 2025 was $720.5 million compared to $559.9 million as of December 31, 2024.

In recent years, there has been a growing trend of an aging patient population and an increasing prevalence of age-associated diseases, underscoring the need for advancing research into the biological ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

These include cytotoxic/cytolytic reactions involving the interaction of IgG or IgM antibodies and complement with a drug allergen (e.g., immune hemolytic anemia and thrombocytopenia), drug ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

However, side effects, like decreased platelets or worsening anemia, have been reported. You may also experience bruising, dizziness, or headaches. Allogenic stem cell transplantation (ASCT) replaces ...